Business Wire

FUNPLUS

Share
DC and FunPlus Collaborate to Bring The Joker to “State of Survival” in a Thrilling New Story Campaign

FunPlus, a leading mobile game developer and publisher, as well as its KingsGroup studio today announced that The Joker will arrive as a new playable character in the free-to-play strategy game State of Survival , available on both iOS and Android . Licensed by Warner Bros. Interactive Entertainment on behalf of DC, all players who complete the story campaign will have a limited window to permanently unlock The Joker.

Later this fall, horror will grip the Settlement as a terrifying breed of laughing zombies begin to attack settlers. When a stranger in a purple suit claims to have survived an attack and volunteers to help, players will embark on a story campaign brimming with intrigue, mystery, and perhaps even betrayal! Check out the teaser trailer here and get ready for the most devious crossover of the year!

“Welcoming a notorious Super-Villain like The Joker to State of Survival and working with an entertainment powerhouse like DC is a huge honor. We are excited to deliver this blockbuster collaboration to our existing players and look forward to welcoming DC fans to check out our post-apocalyptic world in the game,” said Chris Petrovic, Chief Business Officer, FunPlus. “State of Survival has had a phenomenal 2021, and we have no plans to slow down any time soon!”

FunPlus recently announced that State of Survival has passed 100 million downloads, just in time to celebrate the game’s second anniversary.

For more information on DC, visit dccomics.com . For more information on FunPlus, visit http://www.funplus.com . For more information on State of Survival, visit https://funplus.com/games/state-of-survival/ . Find a link to assets here and the teaser trailer here .

About FunPlus

Founded in 2010, FunPlus is a world-class, independent game developer and publisher headquartered in Switzerland and with operations in China, Japan, Singapore, Spain, Sweden, Russia, and the United States.

As an organization that fosters the best creative and diverse talent in the world and employs nearly 2,000 people, the company has developed and published games that have ranked in the #1 spot in nearly 70 countries, including State of Survival, King of Avalon and Guns of Glory.

FunPlus studios include KingsGroup, Puzala, Seven Games and Imagendary Studios, each with a focus on developing a unique brand of innovative games for global audiences.

FunPlus is the founder of FPX (FunPlus Phoenix), one of the world's most successful esports organizations, and the 2019 League of Legends World Champions.

About Warner Bros. Interactive Entertainment

Warner Bros. Interactive Entertainment is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles. Additional information can be found at www.wbgames.com .

About DC

DC is one of the largest English-language publishers of comics and graphic novels in the world and home to some of the most iconic and recognizable characters ever created. As a creative unit of WarnerMedia, DC is charged with strategically integrating its stories and characters across film, television, consumer products, home entertainment, interactive games, and the DC UNIVERSE INFINITE digital subscription service and community engagement portal. For more information visit dccomics.com and dcuniverseinfinite.com .

™ & © DC Comics. ™ & © Warner Bros. Entertainment Inc. (s21)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 13:00:00 CET | Press release

New data from the ongoing FLEX Study highlight the value of real-world evidence in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence c

Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 13:00:00 CET | Press release

First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70–80 years). HER2DX independently predicts long-term survival outcomes in patients treated with trastuzumab with or without chemotherapy. Findings support HER2DX as a tool to guide chemotherapy decisions and de-escalation strategies in older adults. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 12:30:00 CET | Press release

Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submissionCompany now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026Cash position of $185.9 million as of September 30, 2025Conference call on November 4 at 8 am ET (1 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mont

TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 12:00:00 CET | Press release

TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors

Celonis Unveils Platform Innovations to Power the AI-Driven, Composable Enterprise4.11.2025 11:00:00 CET | Press release

Celonis, a global leader in Process Intelligence, today at Celosphere 2025 announced major platform innovations that power enterprise AI to reinvent and continuously improve business operations. Daniel Brown, Chief Product Officer at Celonis, emphasized the need for a structured approach to agentic AI. “To truly operationalize AI, you need to identify the right use cases, redesign your business processes, and orchestrate the agents alongside your people and existing systems," Brown said. "Our enhanced capabilities empower our customers and their partners to build AI solutions that lift their operations to unprecedented levels of efficiency and agility.” The Celonis Process Intelligence Platform extracts raw data from systems, applications and devices within and across enterprises. It enriches this data with customers’ unique business context to create a living digital twin of operations—the Process Intelligence Graph. On top of the Graph, the Process Intelligence Platform provides the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye